Ownership and insider activity for Korro Bio, Inc. (KRRO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Price
| Price | $11.98 |
| Market Cap | $119M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-11 | FORMELA JEAN FRANCOIS | S-Sale | 8,450 | $118K |
| 2026-09-14 | FORMELA JEAN FRANCOIS | S-Sale | 31,888 | $450K |
| 2026-09-11 | FORMELA JEAN FRANCOIS | S-Sale | 1,750 | $24K |
| 2026-09-14 | FORMELA JEAN FRANCOIS | S-Sale | 6,602 | $93K |
| 2026-09-11 | Dolan Oliver | S-Sale | 5 | $69 |
| 2026-09-08 | Dolan Oliver | S-Sale | 7,347 | $99K |
| 2026-09-09 | Dolan Oliver | S-Sale | 6 | $82 |
| 2026-08-26 | FORMELA JEAN FRANCOIS | S-Sale | 249 | $3K |
| 2026-08-26 | FORMELA JEAN FRANCOIS | S-Sale | 51 | $712 |
| 2026-08-19 | FORMELA JEAN FRANCOIS | S-Sale | 23,584 | $330K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.9M | $42.2M | $200.2M | $220.3M | $79.6M | $36.9M | $166.2M | $55.6M | $21.8M |
| Short-term Investments | 0 | 0 | $17.2M | 0 | $51.1M | $18.9M | 0 | $70.5M | $53.3M |
| Receivables | 0 | $161000 | $805000 | $340000 | $144000 | 0 | 0 | $1.7M | $969000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $18.0M | $42.9M | $221.4M | $225.1M | $134.7M | $57.1M | $172.7M | $131.5M | $82.4M |
| Property, Plant & Equipment | $1.7M | $1.5M | $1.8M | $37.8M | $36.9M | $11.9M | $42.8M | $51.5M | $16.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $19.8M | $44.5M | $223.2M | $264.7M | $185.4M | $73.7M | $221.7M | $226.2M | $113.5M |
| Accounts Payable | $994000 | $1.9M | $1.2M | $5.5M | $2.7M | $2.6M | $7.3M | $4.0M | $1.7M |
| Short-term Debt | 0 | 0 | 0 | $397000 | $2.6M | $2.9M | 0 | 0 | 0 |
| Total Current Liabilities | $2.2M | $3.8M | $52.8M | $26.6M | $11.4M | $8.7M | $19.5M | $15.0M | $11.9M |
| Long-term Debt | $46.7M | $84.9M | 0 | $15.0M | $14.2M | $163.9M | 0 | 0 | 0 |
| Total Liabilities | $49.4M | $89.1M | $55.9M | $72.2M | $54.5M | $172.8M | $51.8M | $65.8M | $62.1M |
| Retained Earnings | -$29.9M | -$49.1M | -$68.9M | -$95.4M | -$180.1M | -$101.8M | -$183.0M | -$266.6M | -$383.8M |
| Total Equity | -$29.6M | -$48.3M | $167.4M | $192.5M | $130.8M | -$99.0M | $169.9M | $160.4M | $51.4M |
| Total Debt | $46.7M | $84.9M | 0 | $46.0M | $45.6M | $167.0M | $33.2M | $44.8M | $43.5M |
| Net Debt | $28.8M | $42.7M | -$217.4M | -$174.3M | -$85.1M | $111.1M | -$132.9M | -$81.3M | -$31.7M |
| Working Capital | $15.7M | $39.2M | $168.6M | $198.4M | $123.3M | $48.4M | $153.2M | $116.6M | $70.4M |
Financial Health
| Debt / Equity | 0.41 |
| Current Ratio | 9.55 |
Profitability
| Return on Equity | -114.26% |
| Return on Invested Capital | -49.21% |
| Return on Assets | -65.25% |
| Gross Margin | 72.75% |
| Operating Margin | -3176.57% |
| Net Margin | -4477.08% |
Related companies: ALT · AMRN · ANNX · ANRO · AURA · DBVT · ENGN
Explore sector: Healthcare · Biotechnology
More sections of KRRO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks